98 related articles for article (PubMed ID: 29374695)
1. Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
Matuura H; Miyamoto M; Takano M; Soyama H; Aoyama T; Yoshikawa T; Kato K; Sakamoto T; Kuwahara M; Takasaki K; Ishibashi H; Iwahashi H; Tsuda H; Furuya K
Anticancer Res; 2018 Feb; 38(2):717-722. PubMed ID: 29374695
[TBL] [Abstract][Full Text] [Related]
2. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
[TBL] [Abstract][Full Text] [Related]
3. HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
Kim SK; Cho NH
Int J Clin Exp Pathol; 2014; 7(7):4222-30. PubMed ID: 25120802
[TBL] [Abstract][Full Text] [Related]
4. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
5. HER2 expression in ovarian mucinous carcinomas in Tunisia.
Missaoui N; Abdelkarim SB; Ayachi M; Hmissa S; Yaacoubi MT
Asian Pac J Cancer Prev; 2014; 15(19):8121-5. PubMed ID: 25338994
[TBL] [Abstract][Full Text] [Related]
6. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
7. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
8. CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
Motohara T; Fujimoto K; Tayama S; Narantuya D; Sakaguchi I; Tashiro H; Katabuchi H
Obstet Gynecol; 2016 Jun; 127(6):1003-1011. PubMed ID: 27159753
[TBL] [Abstract][Full Text] [Related]
9. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
10. Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis.
Kim SK; Song SY; Kim S; Cho NH; Yim GW; Kim SW; Kim YT; Nam EJ
Int J Clin Exp Pathol; 2014; 7(8):5103-10. PubMed ID: 25197383
[TBL] [Abstract][Full Text] [Related]
11. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
12. Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Sakamoto T; Kakimoto S; Iwahashi H; Tsuda H; Takano M
J Ovarian Res; 2021 Feb; 14(1):33. PubMed ID: 33583413
[TBL] [Abstract][Full Text] [Related]
13. Stromal p16 expression is significantly increased in malignant ovarian neoplasms.
Yoon N; Yoon G; Park CK; Kim HS
Oncotarget; 2016 Oct; 7(40):64665-64673. PubMed ID: 27572321
[TBL] [Abstract][Full Text] [Related]
14. Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors.
Nissi R; Talvensaari-Mattila A; Kuvaja P; Pääkkö P; Soini Y; Santala M
Anticancer Res; 2015 Feb; 35(2):973-6. PubMed ID: 25667483
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of BTG3 was linked to carcinogenesis, aggressiveness, and prognosis of ovarian carcinoma.
Deng B; Zhao Y; Gou W; Chen S; Mao X; Takano Y; Zheng H
Tumour Biol; 2013 Oct; 34(5):2617-24. PubMed ID: 23657964
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor.
Nagata C; Kobayashi H; Sakata A; Satomi K; Minami Y; Morishita Y; Ohara R; Yoshikawa H; Arai Y; Nishida M; Noguchi M
Pathol Int; 2012 Jul; 62(7):471-6. PubMed ID: 22726067
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of stromal microinvasion in the intestinal type of ovarian mucinous adenocarcinoma.
Kong KY; Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Ann Surg Oncol; 2011 Nov; 18(12):3462-8. PubMed ID: 21556953
[TBL] [Abstract][Full Text] [Related]
18. Emergence of CA125 immunoreactivity in recurrent or metastatic primary ovarian mucinous neoplasms of the intestinal type.
Miller K; Millar J; McCluggage WG
Am J Surg Pathol; 2011 Sep; 35(9):1331-6. PubMed ID: 21836488
[TBL] [Abstract][Full Text] [Related]
19. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
20. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.
Zhang J; Chang B; Liu J
Hum Pathol; 2013 Sep; 44(9):1882-9. PubMed ID: 23664487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
